ReNeuron Stroke Stem Cell Therapy Advances
Executive Summary
Encouraging early data from a Phase II trial of ReNeuron’s stem cell therapy CTX are adding to the evidence that it can improve patients with stroke disability, setting the stage for a pivotal trial next year.
You may also be interested in...
ReNeuron Outlines First-To-Market Plans For Stroke Disability Cell Therapy
ReNeuron has high hopes of being the first to reach the US market with a novel stem cell therapy for use in patients with disabilities caused by stroke – CEO Olav Hellebø outlines the company's plans for Phase III and eventual commercialization.
Cell therapy company raises £68m to go it alone down R&D path
UK cell therapy company ReNeuron has raised £68.4m to advance two of its pipeline programs to regulatory filing stages.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.